Facilities & Capabilities

  • 5 distinct GMP facilities in Atlantic Canada 
    • Headquarters and 4 complex chemistry facilities in Charlottetown, Prince Edward Island
    •  Biologics manufacturing in Windsor, Nova Scotia
  • +25,000 m²  manufacturing facility space
  • 118,000 L of chemical reactor space (20 L to 18,000 L)
  • 64,000 L of fermentation bioreactor capacity (30 L to 17,000 L)
  • Various development and GMP manufacturing areas providing different types of capabilities, including:
    • Class 100,000 (ISO 8/ Grade D) and 10,000 (ISO 7/ Grade C) controlled suites
    • Highly Potent API Band 3 and 4 containment suites
    • Commercial synthetic API manufacturing
    • Commercial biologic drug substance production
    • Full biologics development and characterization
    • Multi-Reactor System and scale down high throughput setup 
    • Continuous processing/flow chemistry equipment
    • Analytical development and 24/7 quality control
  • Multiple qualified GMP storage areas (-80°C to 2-8°C) for raw materials, cell lines, and drug substances
slide2
slide3
slide4
slide5
slide6
slide7
slide8
slide9
slide10
slide11
slide12


Facility

Synthetic Small Molecules

Fermented Small Molecules

Highly Potent APIs

Bioreagents

Biologics

Regulatory Inspection History
Research & Development

17 Hillstrom Ave., PE

  • Lab
  • Pilot
  • Non-GMP Commercial scale
  • Lab
  • Pilot
  • Lab
  • Pilot
  • Commercial
  • Lab
  • Pilot, Non-GMP


Headquarters

11 Aviation Ave., PE

  • Pilot, GMP, Classified
  • Commercial GMP
  • Large-scale Commercial GMP
  • Pilot GMP
  • Commercial GMP
  • Lab
  • Pilot
  • Commercial
  • Commercial GMP


New API Facility

11 Aviation Ave., PE

  • Lab GMP
  • Large-scale Commercial GMP
Large Scale Biomanufacturing Facility

24 Ivey Lane, NS

  • Lab
  • Pilot
  • Clinical
  • Large-scale commercial

*Expected 2022
Dedicated Facility

29 McCarville St., PE

Dedicated Natural Extraction

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors